

# Jermaine I Coward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3501417/publications.pdf>

Version: 2024-02-01

52  
papers

4,591  
citations

218677

26  
h-index

233421

45  
g-index

52  
all docs

52  
docs citations

52  
times ranked

9112  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy for the treatment of perineural spread in cutaneous head and neck squamous cell carcinoma: Time to rethink treatment paradigms. <i>Head and Neck</i> , 2022, 44, 1099-1105.	2.0	6
2	Therapeutic implications of immune profiling and EGFR expression in salivary gland carcinoma. <i>Head and Neck</i> , 2021, 43, 768-777.	2.0	14
3	Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study Results. <i>Cancers</i> , 2021, 13, 3196.	3.7	3
4	Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites. <i>Frontiers in Immunology</i> , 2021, 12, 624434.	4.8	12
5	A Retrospective Cross-Sectional Cohort Trial Assessing the Prevalence of MTHFR Polymorphisms and the Influence of Diet on Platinum Resistance in Ovarian Cancer Patients. <i>Cancers</i> , 2021, 13, 5215.	3.7	1
6	Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma. <i>Cancers</i> , 2020, 12, 869.	3.7	7
7	A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1059-1074.	1.9	6
8	A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3155-TPS3155.	1.6	1
9	Abstract CT166: TRX-E-002-1 in treatment-refractory ovarian cancer - 3-month follow-up results from a phase I study dose escalation phase. , 2020, , .		0
10	384...A Phase 1 study to evaluate the safety, PK, and antitumor activity of AK117, an anti-CD47 monoclonal antibody, in subjects with relapsed/refractory advanced or metastatic solid tumors or lymphomas. , 2020, , .		1
11	Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2554-2554.	1.6	11
12	Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). <i>Journal of Clinical Oncology</i> , 2019, 37, 5501-5501.	1.6	46
13	A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105. <i>Journal of Clinical Oncology</i> , 2019, 37, e14006-e14006.	1.6	3
14	L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution. <i>Cell Reports</i> , 2018, 23, 3730-3740.	6.4	43
15	Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy. <i>Oral Oncology</i> , 2017, 66, 81-86.	1.5	42
16	Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1626-1635.	1.1	81
17	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	10.7	451
18	Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2017, 82, 128-136.	2.8	215

#	ARTICLE	IF	CITATIONS
19	The influence of cisplatin de-escalation on survival outcomes in oropharyngeal head and neck squamous cell carcinoma (OPC).. Journal of Clinical Oncology, 2017, 35, e17551-e17551.	1.6	0
20	Mucinous ovarian cancer: A therapeutic review. Critical Reviews in Oncology/Hematology, 2016, 102, 26-36.	4.4	38
21	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology, 2016, 102, 37-46.	4.4	219
22	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. British Journal of Cancer, 2016, 114, 417-426.	6.4	35
23	Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene, 2016, 35, 468-478.	5.9	45
24	New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health, 2015, 7, 189.	2.6	93
25	EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface. Oncogene, 2015, 34, 1375-1383.	5.9	33
26	The Tolerability of Sunitinib in Elderly Patients with Metastatic Renal Cancer. Clinical Oncology, 2015, 27, 371-372.	1.4	0
27	The role of interleukin-6 in malignant mesothelioma. Translational Lung Cancer Research, 2015, 4, 55-66.	2.8	30
28	Ploidy as a biomarker for targeting metabolism in ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16563-e16563.	1.6	0
29	PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene, 2014, 33, 3561-3570.	5.9	72
30	Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Frontiers in Oncology, 2014, 4, 123.	2.8	147
31	An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B <sub>12</sub> and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity. BMJ Open Respiratory Research, 2014, 1, e000061.	3.0	2
32	38 Patterns of relapse and detection method in patients with resected non-small cell lung cancer (NSCLC) â€” a single institution experience. Lung Cancer, 2014, 83, S15.	2.0	0
33	Interleukin-6: An angiogenic target in solid tumours. Critical Reviews in Oncology/Hematology, 2014, 89, 129-139.	4.4	112
34	Serum HE4 as a prognostic marker in endometrial cancer â€” A population based study. Gynecologic Oncology, 2014, 132, 159-165.	1.4	86
35	33 Outcomes of patients undergoing adjuvant platinumâ€”vinorelbine chemotherapy for resected non-small cell lung cancer (NSCLC). Lung Cancer, 2013, 79, S12.	2.0	1
36	A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. British Journal of Cancer, 2013, 109, 2295-2300.	6.4	65

#	ARTICLE	IF	CITATIONS
37	Chemotherapy advances in small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S565-78.	1.4	75
38	Paraneoplastic Thrombocytosis in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 610-618.	27.0	651
39	A Dynamic Inflammatory Cytokine Network in the Human Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2012, 72, 66-75.	0.9	189
40	A phase II study of 18F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12 weeks. <i>European Journal of Cancer</i> , 2012, 48, 68-74.	2.8	28
41	The role of interleukin-6 in gynaecological malignancies. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 333-342.	7.2	25
42	True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 75, 133-135.	2.0	4
43	Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report. <i>Medical Oncology</i> , 2012, 29, 2623-2625.	2.5	5
44	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , 2011, 11, 719-725.	28.4	1,084
45	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	7.0	217
46	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6083-6096.	7.0	330
47	IL-6 and Ovarian Cancer Response. <i>Clinical Cancer Research</i> , 2011, 17, 7838-7838.	7.0	2
48	Targeting Inflammatory Pathways in Epithelial Ovarian Cancer. , 2011, , 133-164.		0
49	Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age ≥ 70 Years) with Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2008, 20, 142-147.	1.4	5
50	The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 371-377.	2.0	29
51	Time and chemotherapy treatment trends in the treatment of elderly patients (age ≥ 70 years) with small cell lung cancer. <i>British Journal of Cancer</i> , 2006, 94, 18-21.	6.4	20
52	The effects of capecitabine in Raynaud's disease: a case report. <i>Annals of Oncology</i> , 2005, 16, 835-836.	1.2	6